ICD-10-PCS › X New Technology › XW Anatomical Regions › XW0 New Technology, Anatomical... › XW043C3

XW043C3

Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3

RetiredICD-10-PCS procedure code.

No longer in the code set. Submitting it will not be accepted for a current date of service.

Billable FY2018 to FY2021. In the code set FY2018 to FY2021, and removed after that.

Use instead:

  • XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021
  • XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021
  • XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021
  • XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021
  • XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021
  • XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021
  • XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 stated for FY2021

What has happened to this code

Every change the publisher made, from 2018 to now.

  1. FY2018 Added to the code set Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3
  2. FY2022 Removed from the code set

What this code says

Each character is read in its own position, so the same letter means different things in different places. Definitions are CMS's own.

3. Root operation Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

5. Approach Percutaneous

Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure

Codes in the same group

CodeDescriptionStatus
XW00X27 Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 Retired
XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Valid
XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Valid
XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Valid
XW0134C Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 Valid
XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 Valid
XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Retired
XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 Valid
XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Valid
XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Valid
XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Valid
XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Valid